A 4-month rifampin regimen was found to be cheaper than a 9-month course of isoniazid for the treatment of latent tuberculosis in a cost-comparison study published in the Annals of Internal Medicine. Currently, isoniazid is the standard of treatment in most countries for latent tuberculosis infection. The finding that 4 months rifampin treatment is cheaper adds to previously published evidence that this treatment is as effective, while also significantly safer and more likely to be completed, than 6 months or 9 months isoniazid treatment. These findings have the potential to change the way latent tuberculosis is treated.
An estimated one quarter of the global population has latent tuberculosis infection. If left untreated, 10 percent of these 1.7 billion people will develop tuberculosis disease. Latent tuberculosis infection treatment is not new. Monotherapy with isoniazid for 6 to 12 months has been long proven to reduce the risk for developing active tuberculosis by up to 90 percent. The long treatment duration and the fear of serious, even fatal adverse events have limited acceptance and completion.
Researchers from McGill University studied data from two multicenter randomized clinical trials conducted in adults and children with risk factors for developing tuberculosis. They compared health care use and associated costs of treatment with 4 months of rifampin and 9 months of isoniazid in these studies. The analysis indicated that latent tuberculosis infection treatment with 4 months of rifampin resulted in less health service use and significantly lower costs than 9 months of isoniazid for both adults and children. These trials included participants from diverse treatment settings in 9 countries. According to the researchers, these findings suggest that tuberculosis programs in all countries should consider adoption of the 4-month rifampin regimen as a first-line therapy for latent tuberculosis infection.
Short-course rifamycin-based regimens preferred for latent TB
Annals of Internal Medicine (2020). https://www.acpjournals.org/doi/10.7326/M19-3741
Rifampin regimen found to be cheaper than isoniazid for latent tuberculosis (2020, June 16)
retrieved 16 June 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022